Daniel Engelman to Mass Drug Administration
This is a "connection" page, showing publications Daniel Engelman has written about Mass Drug Administration.
Connection Strength
1.008
-
Mow M, Thean LJ, Parnaby M, Mani J, Rafai E, Sahukhan A, Kama M, Tuicakau M, Kado J, Romani L, Engelman D, Whitfeld M, Kaldor J, Steer A, Carvalho N. Costs of mass drug administration for scabies in Fiji. PLoS Negl Trop Dis. 2022 02; 16(2):e0010147.
Score: 0.187
-
Engelman D, Marks M, Steer AC, Beshah A, Biswas G, Chosidow O, Coffeng LE, Lardizabal Dofitas B, Enbiale W, Fallah M, Gasimov E, Hopkins A, Jacobson J, Kaldor JM, Ly F, Mackenzie CD, McVernon J, Parnaby M, Rainima-Qaniuci M, Sokana O, Sankara D, Yotsu R, Yajima A, Cantey PT. A framework for scabies control. PLoS Negl Trop Dis. 2021 09; 15(9):e0009661.
Score: 0.182
-
Engelman D, Cantey PT, Marks M, Solomon AW, Chang AY, Chosidow O, Enbiale W, Engels D, Hay RJ, Hendrickx D, Hotez PJ, Kaldor JM, Kama M, Mackenzie CD, McCarthy JS, Martin DL, Mengistu B, Maurer T, Negussu N, Romani L, Sokana O, Whitfeld MJ, Fuller LC, Steer AC. The public health control of scabies: priorities for research and action. Lancet. 2019 Jul 06; 394(10192):81-92.
Score: 0.155
-
Romani L, Marks M, Sokana O, Nasi T, Kamoriki B, Cordell B, Wand H, Whitfeld MJ, Engelman D, Solomon AW, Kaldor JM, Steer AC. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis. 2019 05; 19(5):510-518.
Score: 0.154
-
Romani L, Marks M, Sokana O, Nasi T, Kamoriki B, Wand H, Whitfeld MJ, Engelman D, Solomon AW, Steer AC, Kaldor JM. Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial. Lancet Glob Health. 2018 10; 6(10):e1132-e1138.
Score: 0.148
-
Lake SJ, Engelman D, Zinihite J, Sokana O, Boara D, Nasi T, Gorae C, Osti MH, Phelan S, Parnaby M, Grobler AC, Schuster T, Andrews R, Whitfeld MJ, Marks M, Romani L, Steer AC, Kaldor JM. One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial. PLoS Negl Trop Dis. 2023 03; 17(3):e0011207.
Score: 0.050
-
Marks M, McVernon J, McCarthy JS, Enbiale W, Hanna C, Chosidow O, Engelman D, Asiedu K, Steer A. Diagnostics to support the control of scabies-Development of two target product profiles. PLoS Negl Trop Dis. 2022 08; 16(8):e0010556.
Score: 0.049
-
Lake SJ, Phelan SL, Engelman D, Sokana O, Nasi T, Boara D, Gorae C, Schuster T, Grobler AC, Osti MH, Andrews R, Marks M, Whitfeld MJ, Romani L, Kaldor J, Steer A. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study). BMJ Open. 2020 08 30; 10(8):e037305.
Score: 0.042
-
Marks M, Romani L, Sokana O, Neko L, Harrington R, Nasi T, Wand H, Whitfeld MJ, Engelman D, Solomon AW, Kaldor JM, Steer AC. Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin. Clin Infect Dis. 2020 04 10; 70(8):1591-1595.
Score: 0.041